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Clinical Trial of a New Diuretic-Metindamide
P. BURGER, 1. F. ANDERSON
SUMMARY
A controlled clinical trial of metindamide (N-(3-sulphamoyl
1 - 4 chlorobenzamido) - 2 - methyl indoline), is reported. It
was compared with furosemide in 15 normal subjects and
15 patients with cardiac oedema. Metindamide was found
to be at least as effective as furosemide, and produced
a greater water loss, but an equivalent electrolyte loss.
It had a slow onset, and a fairly prolonged effect, making
it a less aggressive drug than furosemide, and one which
is suitable for maintenance therapy.
In a smaller trial its effect as a hypotensive agent was
demonstrated. The drug was well tolerated and side-effects
were minimal.
s. Afr. Med. J., 48, 546 (1974).
Preliminary reports from the Continent' indicate that
S 1520 merits further attention, being an agent with a
fairly smooth prolonged action, but equally as potent as
furosemide. It appears to act on the proximal tubule or the
ascending loop of Henle much like mefruside.
PATIENTS AND METHODS
A recent comparative study of two diuretics was so effi-
cient" that its format has been largely adopted here. In
the event, 4 X 5 mg (20 mg) of S 1520 and furosemide
40 mg were used in an open comparative trial. The trial
was divided into 2 parts-normal subjects and patients.
Normal Subjects
Fifteen adult male Black patients convalescing from
minor surgical or orthopaedic procedures, and without
evidence of fluid retention or impairment of renal function,
agreed to participate as a control group. They were on a
standard ward diet and consumed fluids ad lib.
Patients
Fifteen adult Blacks of both sexes with clinically obvious
fluid retention, all due to congestive heart failure, were
selected. Their ages ranged from 25 to 75 years and all
agreed to participate in the trial.
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Throughout the trial period they remained at bedrest
and on a standard ward diet. The cardiac condition was
initially stabilised by a few days' stay in bed and all were
maintained on digoxin. -
In both groups, each subject provided 9 24-hour urine
specimens, while alternately on S 1520 and furosemide.
This was done with a control 24-hour period between each
dosing day. Thus the first 24 hours represented a control
period; day 2 S 1520; day 3 control; day 4 furosemide;
day 5 control; day 6 S 1520; day 7 control; day 8 furo-
semide; and day 9 final control collection. The sequence
of giving a diuretic was therefore in a given order with
a control day between each dose. Although the sequence
adopted and the nature of the tablets were known to the
investigator, (an open comparative trial), this was regarded
as being of minor significance as we were dealing with
objective measurements. The bladder was emptied at 0800
and the urine discarded. The drug was administered in
a single dose and urine was thereafter collected every 4
hours; i.e. at 0800, 1200, 1600, 2000, and a final 12-hour
collection up to 0800. The latter was done because of diffi-
culties at this hospital in obtaining overnight collections.
In both groups, the urine collected during each period
was measured for volume, specific gravity, sodium, potas-
sium and chloride. In addition daily serum sodium, potas-
sium, cWoride, uric acid, urea, and creatinine were esti-
mated. On the full 24-hour urine specimen a creatinine
clearance was calculated.
All subjects were weighed on the first day and every
morning thereafter. The blood pressure was recorded supine
and erect 4 times a day at set times.
Patients With Hypertension
The aim of the trial was primarily that of assessing
diuretic potency. This agent, like other members of the
group, is reputed to have a hypotensive action. Therefore
5 patients with hypertension, under basal conditions but
on no therapy, were given 25 mg of S 1520 daily for 6
successive days. The blood pressures were taken 4 times a
day and the averages calculated for the 6 days.
RESULTS
The nature and type of response to the drugs were different.
Figures for controls are given in Table I and for patients
in Table H. The urine volumes and electrolytes are
expressed as mean values (± SD) for normals and patients
in Table Ill. The mean blood pressure for normals and
patients is given in Table IV.
. The mean and standard deviations were calculated for
the following parameters: mean blood pressure; total
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TABLE I. CONTROLS
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
68,35 68,30 67,79 68,17 67,73 68,15 67,57 68,12 67,75
135/78 131/79 132/77 136/77 136/77 137/78 134/76 137/76 135/77
136/79 130/74 136/78 130/74 137/79 129/75 137/78 130/75 137/77
131/77 132/77 129/76 132/75 132/76 133/77 131/75 133/76 133/75
132/78 129/73 133/77 127/72 134/77 126/73 134/77 130/74 136/76
353,3 660,0 303,3 741,7 435,8 401,7 406,7 683,3 405,0
284,6 670,0 353,3 361,7 260,0 490,3 216,7 270,3 211,7
189,0 613,4 410,7 326,8 292,0 687,7 228,0 311,7 250,0
716,7 1004,6 626,7 733,3 562,0 1 033,3 670,0 743,3 783,3
1543,6 2948,0 1 694,0 2163,5 1 599,8 2612,0 1 521,4 2008,6 1 650,0
1 009,1 1 006,2 1 012,1 1 008,1 1 009,1 1 011,9 1 012,1 1 006,5 1 013,5
1 012,9 1008,8 1 012,2 1 014,3 1009,5 1 012,0 1 019,3 1 016,9 1 018,4
1 017,2 1 009,5 1 011,1 1 014,1 1 016,9 1006,3 1 021,9 1 015,1 1017,1
1 012,9 1009,4 1 010,7 1 014,3 1 015,7 1009,6 1 014,8 1 018,1 1 013,7
148,48 309,92 257,92 139,52 106,04 255,60 144,16 167,56 133,16
48,84 66,60 59,20 114,58 67,28 94,36 46,24 98,00 49,32
165,96 326,76 203,25 194,57 106,63 234,15 140,15 198,40 156,27
73,5 81,7 80,7 84,5 80,0 89,7 86,3 85,7 83,6
24,9 28,0 28,2 31,0 28,7 26,1 27,5 28,8 27,1
141,2 140,5 139,0 139,2 138,5 139;5 140,9 138,9 139,9
96,6 101,7 101,1 100,2 100,7 98,1 100,9 99,2 101,3
4,37 4,39 4,37 4,15 4,23 4,73 4,32 4,13 4,23
1,03 0,91 1,06 1,04 1,10 0,90 0,91 1,01 1,15
4,62 5,01 5,14 5,29 5,64 5,06 4,97 5,27 5,02
6,46 6,90 7,47 8,71 7,99 8,20 8,38 8,35 8,3
sodium. Student tests with a Bessel correction for small
numbers were carried out for both normal subjects and
patients.
Because there is a carry-over effect with S 1520, all the
resu1ts on diuretic days were compared to the day 1
control values. The first and last control day values were
tested for significant differences as were day 1 and the
highest control day values.
Blood Pressure
The mean blood pressure (mmHg) was calculated in
order to reduce the volume of data.
(Systolic - diastolic)
Mean blood pressure = diastolic +
3
Normal subjects show a reduction in both standing and
lying m~an blood pressures on days when either diuretic
is given. There is no significant difference between the
control day values and the values on the days when
diuretics are taken. In the patients both standing and lying
mean blood pressures fell on the days when S 1520 was
given, and rose o!" remained the same on the days when
furosemiae was given. There was no significant difference
between day 1 values and any of the diuretic days. Thus
there could have been no significant difference between
the diuretics with regard to the acute effect on blood
pressure.
Total Urinary Volume
S 1520 and furosemide produced a highly significant
urinary volume increase in both patients and normal sub-
jects. However, the volume excretion in normal subjects
was significantly greater with S 1520 than with furosemide.
·Furosemide produced a greater response in patients than
in normal subjects.
24·Hour Potassiums
For both patients and normal subjects all the mean
potassium excretions were significantly higher on days
when diuretics were given than on the first control day.
In the normal subjects, there was a significantly higher
potassium excretion on control day 5 (after furosemide)
than on control day 1. In patients there was a significantly
higher potassium loss on control days 3 and 7 (after
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TABLE 11. PATIENTS
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Mass (kg) 73,69 74,0· 72,9 72,86 71,16 71,7 70,99 70,47 69,69
Blood pressure
(mmHg)
Standing 0800 h 148/83 150/81 143/79 148/86 148/83 145/81 143/80 142/80 147/79
Standing 2000 h 146/83 145/80 142/83 148/86 148/83 lSO/80 144/79 144/80 142/81
Lying 0800 h 145/81 145/80 141/78 144/86 144/82 141/81 139/80 138/79 141/79
Lying 2000 h 143/83 142/79 140/83 145/85 143/82 138/80 150/79 142/80 142/80
Urine
Volume of urine (mI)
Period 1 235,4 528,6 723,2 1444,3 313,2 412,5 530,4 1 135,7 319,7
Period 2 190,7 451,8 398,2 530,0 210,7 401,1 275,0 612,1 278,9
Period 3 283,6 861,8 249,3 310,7 257,1 675,7 253,6 512,5 171,4
Period 4 548,6 1 021,4 558,9 523,6 584,3 1 109,3 639,3 562,5 508,9
Total 1 258,3 2863,6 1 929,6 2808,6 1 365,3 2598,6 1 698,3 2822,8 1 278,9
SG of urine
Period 1 1 018,1 1 014,1 1 012,1 1007,6 1 016,9 1 014,5 1 012,7 1 007,1 1 015,6
Period 2 1017,5 1 012,2 1 015,5 1 010,5 1 017,3 1 013,5 1 015,2 1009,4 1 017,0
Period 3 1 015,6 . 1 011,1 1 017,9 1 013,9 1 016,7 1 OIl,S 1 015,7 1 012,5 1 018,4
Period 4 1 015,4 1 010,6 1 015,9 1 014,2 1 014,6 1008,8 1 014,8 1 014,6 1 015,5
Total urinary sodium (mEq) ... 130,47 214,05 138,22 228,56 118,38 194,60 160,17 236,63 121,28
Total urinary potassium (mEq) ... 38,33 112,85 64,55 130,37 48,20 98,52 54,82 126,26 37,22
Total urinary chloride (mEq) 96,86 220,26 196,09 231,75 123,75 215,45 147,78 252,53 127,01
Urinary 24 h creatinine clearance 55,7 56,3 60,3 58,7 57,0 60,4 60,4 56,8 57,2
Blood
Urea (mg/l00 ml) ... 37,6 36,9 37,8 39,6 35,7 38,8 37,6 37,6 37,6
Sodium (mEq) ... 137,1 140,0 140,3 140,4 141,7 140,7 140,8 140,1 140,5
Chloride (mEq) 100,4 100,0 100,3 101,5 100,9 100,9 101,3 100,9 99,8
Potassium (mEq) 4,56 4,57 4,57 4,45 4,54 4,54 4,41 4,44 4,52
Creatinine (mg/l00 ml) ... 1,30 1,19 1,10 1,02 1,26 1,18 1,08 1,18 1,21
Uric acid (mg/l00 ml) ... 5,03 5,10 5,16 5,44 5,29 5,1 5,26 5,27 4,84
Alkaline phosphatase 7,64 7,80 7,20 6,86 7,09 7,76 7,32 7,12 7,46
(King-Armstrong units)
TABLE Ill. URINE VOLUMES AND ELECTROLYTES/24 HOURS IN 15 PATIENTS WITH OEDEMA AND 15 CONTROLS,
MEAN ± SO
Urine vol. Cml) Urinary sodium (mEq) Urinary chlorides CmEq) Urinary potassium (mEq)
Day Normals Patients Normals Patients Normals Patients Normals Patients
1 597 1258 148,5 112,9 166,2 101,5 49,1 36,3
(-+-265) (-+-384) (-+-35,7) (-+-57,4) (-+-32,8) (±64,2) (-+-17,2) (-+-12,0)
2
2882 2942 330,1 214,4 339,9 220,2 69,7 122,1
(-+-429) (-+-498) (-+-98,4) (-+-99,8) (-+-92,8) (-+-67·,8) (-+-17,2) (-+-37,8)
3
1694 1905 170,4 140,3 202,7 198,4 60,7 64,5
(-+-186) (-+-351 ) (-+-35,5) (-+-81,1) (-+-55,4) (-+-98,9) (-+-18,0) (-+-47,2)
4
2132 2801 139,5 219,5 200,4 214,5 124,3 135,7
(-+-152) (-+-870) (-+-39,0) (-+-83,1) (-+-33,2) (-+-101,2) (-+-23,5) (-+-58,8)
5
1532 1365 106,0 117,6 106,6 123,0 65,2 46,0
(±180) (-+-662) (-+-34,3) (-+-38,8) (-+-23,1 ) (-+-47,1) (-+-15,6) (±23,4)
6
2619 2680 255,6 194,3 234,1 217,1 94,3 98,5
(-+-364) (-+-823) (-+-34,5) (-+-83,6) (-+-53,4) (95,9) (-+-28,5) (-+-26,3)
7
1561 1705 145,6 159,8 141,6 153,1 46,2 54,9
(-+-126) (-+-871 ) (-+-49,0) (-+-66,9) (-+-27,0) (-+-85,1) (-+-18,7) (-+-20,3)
8
2015 2659 154,4 230,85 197,9 245,3 95,0 125,5
(-+-225) (-+-690) (-+-23,0) (-+-73,7) (-+-41,5) (-+-77,1) (-+-82,1) (-+-45,5)
9
1690 1300 133,7 124,5 158,2 123,5 SO,1 37,7
(-+-174) (±75) (-+-21,2) (-+-52,1) (-+-37,5) (±31,5) (-+-20,8) (-+-9,9)
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DISCUSSION
The drug was well tolerated and produced no major side-
effects. Pruritus of the skin was noted in 3 patients.






























TABLE IV. BLOOD PRESSURE MEAN -+- SO
Normals (mmHg) Patients (mmHg)
Day Standing Lying Standing Lying
97,67 96,69 104,18 102,11
-+-12,0 -+-12,13 -+-10,97 -+-10,7
2
93,24 92,69 102,54 101,31
-+-11,15 -+-12,94 -+-11,95 -+-10,45
3
100,71 94,93 102,71 101,73
-+-24,07 -+-11,06 -+-9,35 -+-9,09
4
93,22 90,73 106,38 105,58
-+-13,74 -+-13,58 -+-11,14 -+-11 ,39
5
96,93 94,09 104,42 102,47
-+-13,74 -+-8,69 -+-10,3 -+-10,47
6
91,98 92,36 100,22 98,78
-+-10,49 -+-10,77 -+-9,58 -+-10,31
7
96,55 95,44 101,18 99,6
-+-10,88 -+-11 ,45 -+-9,57 -+-10,58
8
93,22 92,27 101,71 100,4
±12,67 -+-12,55 -+-10,2 -+-10,39
9
95,2 95,58 100,96 99,76
-+-11,65 ±11,01 -+-7,59 -+-8,79
S 1520) than on control day 1. This would confirm a carry-
over effect.
24-HoUr Sodiums
In normal subjects S 1520 produced a significant increase
in sodium excretion above day 1 control values. However,
furosemide did not.
In patients, S 1520 and furosemide produced significant
increases in sodium excretion above day 1 control values.
In normal subjects, the sodium excretion was greater with
S 1520 administration than with furosemide administra-
tion.
24-Hour Chlorides
Both S 1520 and furosemide produced a significant
increase in chloride excretion in normal subjects. Similarly,
in patients both diuretics produced a urinary chloride
excretion significantly different from control day 1 values.
Many diuretic trials are partly invalidated by the fact that
comparisons between drugs were made in separate groups
of patients. This trial compared the two drugs directly in
the same group of patients.
The one difficulty encountered was that of the prolonged
action of Metindamide causing a carry-over effect into
the next trial period. .
With this in mind, the following points emerged from
the study: S 1520 in a dose of 20 mg is at least as effective
as 40 mg of furosemide. It produced a significantly greater
sodium and water loss than furosemide, however. The
action of the drug is of rapid onset and it produced a slow
increase in urine volumes, with a maximum after 12 hours
and a strong suggestion of a carry-over effect into the next
control day. No changes in serum uric acid or potassium
levels were noted in the short period under review.
In the short-term study S 1520 had a mild and prolonged
hypotensive action which should make it a useful adjunct
in the antihypertensive armamentarium.
With regard to other diuretics, it compares favourably
with furosemide in terms of potency and with chlorthali-
done in duration of action.
Effect on Hypertensives
The results of this part of the study are shown in
Table V. S 1520 produced a fall in systolic and diastolic
blood pressure. After 6 days' treatment the mean blood
pressure had fallen from 182/112 to 168/102 mmHg.
We wish to thank Servier Laboratories of London for sup-
plying the S 1520 and for the statistical calculations.
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